glp-1 receptor agonists and cancer risk in adults with obesity NEW: A systematic review found that #GLP1 have little or no effect on the for obesity-related cancers. The findings offer insights into the safety of GLP-1RAs suggest no Glucagon-like peptide 1 receptor agonists

[DOI] [PubMed] [Google Scholar] 149.Kei A, Liberopoulos E, Siamopoulos K, Elisaf M

Could become the gold standard once approved

Eligibility for a GLP-1 medication depends on a Service Members diagnosis, prior authorization, and/or medical necessity

The clinical studies have demonstrated the synergistic effects of GIP and GLP-1 agonism on glucose metabolism and body weight in these unimolecular dual agonists (63, 76), marking a significant achievement in the pharmaceutical development of incretins, which will be further discussed in the next section

First submitted to a journal in 1989, the article was finally published in 1992